Semaglutide is a GLP-1 receptor agonist, meaning it mimics a gut hormone that slows digestion and reduces appetite. It is sold as Ozempic for diabetes and Wegovy for weight loss.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates two gut hormone receptors instead of one, which produces stronger appetite suppression. It is sold as Mounjaro for diabetes and Zepbound for weight loss.

Semaglutide vs Tirzepatide: Which Drops More Weight?

Q: Which causes more weight loss, semaglutide or tirzepatide?

Tirzepatide produces more average weight loss in clinical trials. The SURMOUNT trials showed higher average body weight reduction than the STEP trials for semaglutide, though individual results vary [verify: source].

Q: Can you take semaglutide and tirzepatide together?

No. Both drugs work on overlapping GLP-1 receptors. Taking them together offers no extra benefit and may increase side effects. Only one should be used at a time.

Built by medical professionals, gym rats, and experienced biohackers

Tirzepatide drops more weight on average. It hits two hormone targets instead of one, which gives it a stronger appetite-suppressing effect than semaglutide.

Which Drug Causes More Weight Loss?

Semaglutide (Ozempic, Wegovy) targets one gut hormone receptor. It is the more established option with the longer track record. Tirzepatide (Mounjaro, Zepbound) targets two receptors and shows higher average weight loss in head-to-head data . Both require a prescription. For most people who want maximum weight loss, tirzepatide has the edge.

What Is Semaglutide?

Semaglutide is a GLP-1 receptor agonist. That means it copies a gut hormone called GLP-1. GLP-1 slows how fast your stomach empties and signals your brain that you are full.

It comes as a weekly injection. It is FDA-approved as Ozempic (for type 2 diabetes) and Wegovy (for chronic weight management).

Large clinical trials (the STEP program) showed meaningful average body weight reductions .

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates two gut hormone receptors instead of one: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

GIP normally signals your fat cells and your brain. Adding GIP activation to GLP-1 activation may explain why tirzepatide suppresses appetite more strongly .

It is FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss).

How Do They Differ?

Feature	Semaglutide	Tirzepatide
Receptor targets	GLP-1 only	GLP-1 and GIP
Brand names	Ozempic, Wegovy	Mounjaro, Zepbound
Approved use	Type 2 diabetes; chronic weight management	Type 2 diabetes; chronic weight management
Typical dose (weight loss)	Up to 2.4 mg weekly	Up to 15 mg weekly
Average weight loss in trials	Roughly 15% of body weight	Roughly 20 to 22% of body weight
Evidence level	Large-scale human trials (STEP program)	Large-scale human trials (SURMOUNT program)
Approval year (weight loss)	2021	2023

Mechanism. Semaglutide mimics one hormone. Tirzepatide mimics two. Both slow digestion and reduce appetite. Tirzepatide's dual action appears to produce a stronger and more sustained effect on hunger .

Weight loss data. The STEP trials for semaglutide and the SURMOUNT trials for tirzepatide are both high-quality trials. Direct comparisons are complicated by different trial designs. Even so, tirzepatide consistently showed higher average reductions in body weight . Individual results vary significantly.

Side effects. Both cause similar GI side effects: nausea, vomiting, diarrhea, and constipation, especially early on. Tirzepatide's stronger effect may mean stronger side effects for some people. Many users still tolerate it well .

Onset. Both show noticeable appetite suppression within 4 to 8 weeks of starting. Full weight-loss effects develop over 6 to 12 months of consistent use .

How Do You Track a GLP-1 Protocol?

Both drugs involve a gradual dose escalation over several months. People on structured protocols find it helpful to log their dose, weight, and side effects in one place. DoseVault is built for exactly that: tracking what you take, how you titrate, and what you notice along the way.

Can You Take Both Together?

No. Both drugs activate GLP-1 receptors. Taking both at once does not stack the benefits and may increase the risk of side effects. Only one should be used at a time.

Frequently Asked Questions

What is semaglutide?
Semaglutide is a GLP-1 receptor agonist that mimics a gut hormone to slow digestion and reduce appetite. It is sold as Ozempic and Wegovy.

What is tirzepatide?
Tirzepatide activates two gut hormone receptors (GLP-1 and GIP) instead of one, producing stronger appetite suppression. It is sold as Mounjaro and Zepbound.

Which causes more weight loss, semaglutide or tirzepatide?
Tirzepatide shows higher average weight loss in clinical trials, though individual results vary .

Can you take semaglutide and tirzepatide together?
No. They work on overlapping receptors and should not be combined.

Which Do People Pick, and When?

This is general guidance, not personalized medical advice. Both drugs require a prescription. Discuss your options with a licensed clinician.

Choose semaglutide if:
- Your doctor recommends starting with it
- You want the option with the longest track record
- Cost or insurance coverage favors it

Choose tirzepatide if:
- You want the highest average weight-loss potential based on current trial data
- You have already tried semaglutide without enough effect
- Your doctor believes your risk profile supports it

This page is educational only. It is not medical advice and does not replace consultation with a licensed healthcare provider. Both drugs require a prescription. Do not use them to diagnose, treat, cure, or prevent any condition.

Built by medical professionals, gym rats, and experienced biohackers

Managing a dose-escalation protocol? DoseVault lets you log each weekly dose, track weight and side effects, and see your full timeline in one place.